R R

What Is Quizartinib?

Quizartinib is a prescription targeted cancer medication marketed under the brand name Vanflyta. It belongs to the tyrosine kinase inhibitor class and is used to treat adults with newly diagnosed acute myeloid leukemia (AML) carrying an FLT3 internal tandem duplication, or FLT3-ITD, mutation. Quizartinib is administered orally with specific chemotherapy regimens and may continue as maintenance treatment after consolidation chemotherapy. It is not approved for every type of leukemia. Quizartinib carries a boxed warning for QT prolongation, torsades de pointes, and cardiac arrest, requiring specialized monitoring and prescribing restrictions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Quizartinib?

Quizartinib is a prescription targeted cancer medication marketed under the brand name Vanflyta. It belongs to the tyrosine kinase inhibitor class and is used to treat adults with newly diagnosed acute myeloid leukemia (AML) carrying an FLT3 internal tandem duplication, or FLT3-ITD, mutation. Quizartinib is administered orally with specific chemotherapy regimens and may continue as maintenance treatment after consolidation chemotherapy. It is not approved for every type of leukemia. Quizartinib carries a boxed warning for QT prolongation, torsades de pointes, and cardiac arrest, requiring specialized monitoring and prescribing restrictions.

read more about quizartinib ...

Copy this HTML:

Copy HTML Copied!

How Does Quizartinib Work?

Quizartinib inhibits FLT3, a receptor tyrosine kinase involved in the development and survival of certain blood cells. Some patients with AML have an FLT3-ITD mutation that causes abnormal kinase signaling and promotes the growth of leukemia cells. By inhibiting FLT3 activity, quizartinib interferes with signaling that supports the survival and proliferation of these cells. Its treatment effects depend on the leukemia's molecular characteristics and the accompanying chemotherapy regimen. Quizartinib can also affect cardiac electrical activity, making electrocardiogram monitoring necessary throughout treatment.

What Type of Leukemia Does Quizartinib Treat?

Quizartinib is approved for adults with newly diagnosed FLT3-ITD-positive acute myeloid leukemia, confirmed using an FDA-approved test. It is given with standard cytarabine and anthracycline induction chemotherapy, followed by cytarabine consolidation chemotherapy when appropriate. Eligible patients may subsequently receive quizartinib alone as maintenance therapy. It is not approved as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation because improved overall survival has not been demonstrated in that setting. An oncology specialist reviews genetic test results, cardiac health, electrolyte concentrations, and other treatments before prescribing it.

How Should Quizartinib Be Taken?

Quizartinib is taken orally once daily, with or without food, according to a treatment-phase schedule. During induction and consolidation, the recommended dose is 35.4 mg daily on specified days of each chemotherapy cycle. Maintenance treatment generally begins at 26.5 mg daily, with a possible increase to 53 mg daily after 14 days when cardiac monitoring permits. Tablets must be swallowed whole without cutting, crushing, or chewing. Patients require electrocardiograms and potassium and magnesium monitoring before and during treatment. Dose changes may be necessary for QT prolongation or interactions with strong CYP3A inhibitors. Quizartinib is available only through the Vanflyta REMS program.

What Are the Side Effects and Warnings of Quizartinib?

Common adverse effects during treatment can include nausea, vomiting, diarrhea, abdominal pain, headache, low blood cell counts, and abnormal electrolyte levels. Quizartinib carries a boxed warning for QT prolongation, torsades de pointes, and cardiac arrest. It is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or a history of certain serious ventricular arrhythmias. Treatment can also cause embryo-fetal harm. Clinicians monitor electrocardiograms, electrolytes, and medication interactions closely. Fainting, palpitations, severe dizziness, or sudden loss of consciousness requires immediate medical attention.

Common Questions About Quizartinib

Is quizartinib the same as Vanflyta?

Yes. Vanflyta is the brand name for quizartinib, a targeted FLT3 inhibitor used for newly diagnosed FLT3-ITD-positive acute myeloid leukemia in adults.

Does quizartinib treat all types of AML?

No. Quizartinib is approved for newly diagnosed AML with a confirmed FLT3-ITD mutation, using the specified treatment regimen.

Why are ECG tests required during quizartinib treatment?

Quizartinib can prolong the QT interval and cause life-threatening heart rhythm disturbances. ECG testing helps detect these changes before serious complications develop.

Can quizartinib be taken after a stem cell transplant?

Vanflyta is not indicated as maintenance monotherapy following allogeneic stem cell transplantation because an overall survival benefit has not been established in that setting.

References

DailyMed - VANFLYTA (quizartinib) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29cdbcfe-497d-4e78-bb7b-2d4acafe8e86. Date Accessed November 3, 2026.

FDA Approves Quizartinib for Newly Diagnosed Acute Myeloid Leukemia. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia. Date Accessed November 3, 2026.

Quizartinib. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK605695/. Date Accessed November 3, 2026.

Quizartinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a623034.html. Date Accessed November 3, 2026.

Quizartinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Quizartinib. Date Accessed November 3, 2026.